Exome Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Exome Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-65,200	Closed	-$3.69M	–	64
2024 Q4	$3.69M	Sell	65,200 -12,800	-16%	-$715K	2.77%	13
2024 Q3	$4.04M	Buy	+78,000	New	+$3.66M	2.73%	11

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Exome Asset Management's BMY Position: Q1 2025 in Review

Exome Asset Management sold out of Bristol-Myers Squibb (BMY) in Q1 2025, closing a stake of 65,200 shares — an estimated $3.69M sold.

Exome Asset Management first reported a position in BMY in Q3 2024 and held it in 2 quarters. The position peaked at $4.04M in Q3 2024. 2,477 funds tracked by Wall St. Rank hold BMY as of Q1 2025.

Exome Asset Management reported no remaining Bristol-Myers Squibb position as of Q1 2025 after selling out during the quarter.
Exome Asset Management sold 65,200 Bristol-Myers Squibb shares in Q1 2025, an estimated $3.69M.
Exome Asset Management first reported a position in Bristol-Myers Squibb in Q3 2024 and held it in 2 quarters.
Exome Asset Management's Bristol-Myers Squibb position peaked at $4.04M in Q3 2024.
2,477 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2025.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.